BMT CTN Protocol 1102
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome.
Below are protocol-related documents, which may be periodically updated.
- Protocol Synopsis, 5.0 dated November 28, 2018
- Protocol, 5.0 dated November 28, 2018
- Summary of Changes from version 4.0 to version 5.0
- Informed Consent, 4.0 dated July 2, 2015
- Frequently Asked Questions
- This study is posted on clinicaltrials.gov as NCT02016781.
- Key Personnel
Protocol Co-Chair: Ryotaro Nakamura, MD (626-256-4673) rnakamura@coh.org
Protocol Co-Chair: Corey Cutler,MD () cscutler@partners.org
Protocol Officer: Wael Saber, MD414-805-0300) wsaber@mcw.edu
Protocol Coordinators: Alyssa Ramirez (301-251-1161) aramirez@emmes.com
Garett Skelton bmtctn1102@emmes.com
Medical Monitor: Bipin Savini, MD bipin.savini@vanderbilt.edu
The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study.